• Janssen Research and Development LLC, of Raritan, N.J., a unit of Johnson & Johnson, said results from a 52-week analysis of a Phase III trial of Invokana (canagliflozin) showed substantial improvements in glycemic control for patients with Type II diabetes who are inadequately controlled on metformin and a sulfonylurea therapy.